Although GLP-1 receptor agonists (GLP-1 RAs) are not approved for use during pregnancy, periconceptional exposure is increasingly reported. A Danish nationwide study evaluated the association between periconceptional use of liraglutide and semaglutide and obstetric outcomes, analyzing 756,636 singleton pregnancies among 480,231 women. Among these, 529 pregnancies involved periconceptional GLP-1 RA exposure. After adjustment, GLP-1 RA use was associated with an increased risk of preterm birth in women treated for diabetes (liraglutide: aOR 1.70; semaglutide: aOR 1.84).
However, no such association was observed among women using these agents for weight management (liraglutide: aOR 1.01; semaglutide: aOR 0.71). These findings suggest that the elevated risk of preterm birth may be driven by underlying diabetes-related factors rather than GLP-1 RA exposure itself. Should preconception…
